Sulunay Parlar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sulunay Parlar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Vildan Alptüzün
Department of Pharmaceutical Chemistry Faculty of Pharmacy, Ege University Izmir Turkey
7 shared publications - Ayse Hande Tarikogullari
Ege University Faculty of Pharmacy, Department of Pharmaceutical Chemistry, İzmir, Türkiye
2 shared publications - Merve Saylam
İzmir Katip Çelebi University Faculty of Pharmacy, Department of Pharmaceutical Chemistry, İzmir, Türkiye
2 shared publications - Ayca Karasakal
Departmentof Chemistry, Science and Letters Faculty, Tekirdag Namik Kemal University, Tekirdag, Turkey
1 shared publication Ayse H. Tarikogullari
Department of Pharmaceutical Chemistry, Faculty of Pharmacy Ege University Izmir Turkey
1 shared publicationAyse Hande Tarikogullari
Department of Pharmaceutical Chemistry Faculty of Pharmacy, Ege University Izmir Turkey
1 shared publication
Latest Publications
- 31 August 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (2) , 503-516
Synthesis and Biological Evaluation of Tacrine Derivatives as Potential Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer’s Disease
Some tacrine derivatives bearing unsubstituted and para-substituted benzylidene moiety linked to the hydrazine function were synthesized and screened for potential acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. They were purified and structurally characterized by FT-IR, 1H NMR, and ESI-MS spectroscopy, confirming the proposed molecular structures. Their inhibitory activities against AChE and BChE were evaluated using a modified Ellman’s colorimetric assay. All compounds exhibited significant inhibitory potency, with IC50 values ranging from 0.088 to 0.359 µM on AChE and from 0.025 to 0.093 µM on BChE. Among the derivatives, compound 1b bearing a methyl substituent on the benzylidene ring showed the highest AChE inhibition (IC50= 0.088 µM), while the unsubstituted derivative 1a exhibited the highest BChE inhibition (IC50= 0.025 µM). Molecular docking studies were also conducted to elucidate the possible binding mode of the most active compounds (1b for AChE; 1a for BChE), and the ADMET properties of all compounds were predicted using the ADME and toxicity tools of the PreADMET website.
- 31 August 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (2) , 503-516
Synthesis and Biological Evaluation of Tacrine Derivatives as Potential Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer’s Disease
Some tacrine derivatives bearing unsubstituted and para-substituted benzylidene moiety linked to the hydrazine function were synthesized and screened for potential acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. They were purified and structurally characterized by FT-IR, 1H NMR, and ESI-MS spectroscopy, confirming the proposed molecular structures. Their inhibitory activities against AChE and BChE were evaluated using a modified Ellman’s colorimetric assay. All compounds exhibited significant inhibitory potency, with IC50 values ranging from 0.088 to 0.359 µM on AChE and from 0.025 to 0.093 µM on BChE. Among the derivatives, compound 1b bearing a methyl substituent on the benzylidene ring showed the highest AChE inhibition (IC50= 0.088 µM), while the unsubstituted derivative 1a exhibited the highest BChE inhibition (IC50= 0.025 µM). Molecular docking studies were also conducted to elucidate the possible binding mode of the most active compounds (1b for AChE; 1a for BChE), and the ADMET properties of all compounds were predicted using the ADME and toxicity tools of the PreADMET website.
- Open Access
- 6 April 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (4) , e70285
Synthesis, Bioactivity and Molecular Modeling Studies on Benzimidazole Derivatives and Its Isosteres as Potent AChE / BChE and GSK3β Inhibitors for Alzheimer's Disease
A series of benzimidazoles and its analogs (benzoxazoles and benzothiazoles) bearing a benzohydrazide‐hydrazones moiety at the 2‐position were designed and synthesized as potential acetylcholinesterase (AChE) inhibitors. Cholinesterase (ChE) inhibitory activity results showed that all compounds displayed good inhibition of AChE, whereas only some of the compounds were active against BChE. Among the title compounds, it was found that all benzimidazole series were selective towards AChE. Kinetic analysis and molecular modeling studies were conducted on the most active compounds, namely 1j for AChE and 3g for BChE inhibition. The kinetic results showed that the tested compounds exhibited a mixed‐type inhibition mechanism on both enzymes. In cell culture studies, all compounds were evaluated for their neuroprotective effects against hydrogen peroxide (H 2 O 2 )‐induced oxidative stress in the SH‐SY5Y human neuroblastoma cell line. Several compounds demonstrated more than 30% neuroprotection at a low concentration (1 μM) in the presence of H 2 O 2 . Selected compounds, chosen based on their EC 50 values, were further examined for their effects on glycogen synthase kinase‐3 beta (GSK3β), an enzyme whose activity has been reported to be increased in the brains of patients with Alzheimer's disease (AD). The inhibition of GSK3β was assessed by measuring phosphorylated GSK3β (pGSK3β, Ser9) protein expression via Western Blot analysis under oxidative stress conditions. Among the tested compounds, 1l , 2b , 2j , and 3l significantly increased pGSK3β (Ser9) protein levels compared to cells treated with tideglusib, a known GSK3β inhibitor.
- 6 April 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (4) , e70285
Open AccessSynthesis, Bioactivity and Molecular Modeling Studies on Benzimidazole Derivatives and Its Isosteres as Potent AChE / BChE and GSK3β Inhibitors for Alzheimer's Disease
A series of benzimidazoles and its analogs (benzoxazoles and benzothiazoles) bearing a benzohydrazide‐hydrazones moiety at the 2‐position were designed and synthesized as potential acetylcholinesterase (AChE) inhibitors. Cholinesterase (ChE) inhibitory activity results showed that all compounds displayed good inhibition of AChE, whereas only some of the compounds were active against BChE. Among the title compounds, it was found that all benzimidazole series were selective towards AChE. Kinetic analysis and molecular modeling studies were conducted on the most active compounds, namely 1j for AChE and 3g for BChE inhibition. The kinetic results showed that the tested compounds exhibited a mixed‐type inhibition mechanism on both enzymes. In cell culture studies, all compounds were evaluated for their neuroprotective effects against hydrogen peroxide (H 2 O 2 )‐induced oxidative stress in the SH‐SY5Y human neuroblastoma cell line. Several compounds demonstrated more than 30% neuroprotection at a low concentration (1 μM) in the presence of H 2 O 2 . Selected compounds, chosen based on their EC 50 values, were further examined for their effects on glycogen synthase kinase‐3 beta (GSK3β), an enzyme whose activity has been reported to be increased in the brains of patients with Alzheimer's disease (AD). The inhibition of GSK3β was assessed by measuring phosphorylated GSK3β (pGSK3β, Ser9) protein expression via Western Blot analysis under oxidative stress conditions. Among the tested compounds, 1l , 2b , 2j , and 3l significantly increased pGSK3β (Ser9) protein levels compared to cells treated with tideglusib, a known GSK3β inhibitor.
- 13 January 2026
- Published by ACG Publications in Bioorganic and Medicinal Chemistry Reports
- Vol. 9 (1)
Synthesis and inhibitory activity of novel N-phenethylpiperidinehydrazide hydrazones against acetylcholinesterase, butyrylcholinesterase, and β-Amyloid (1–42) as potential anti-Alzheimer agents
Novel N-phenethylpiperidine-hydrazide hydrazones were synthesized and evaluated for their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with the most active compounds additionally assessed for their in vitro inhibition of ?-amyloid 42 (A?42) self-aggregation. The synthesized compounds were purified and structurally characterized using FT-IR, ¹H-NMR,13C-NMR, ESI-MS spectroscopy, and elemental analysis. All compounds exhibited inhibitory activity against AChE with IC50 values ranging from 6.32 to 8.24 µM, while some compounds showed moderate inhibition of BChE enzyme. Compound 3g (IC50= 6.32 ± 0.27 µM) and 3i (IC50= 6.32 ± 0.25 µM) showed the highest AChE inhibition, whereas compound 3a exhibited the highest BChE inhibition (IC50= 8.27 ± 0.34 µM). The most potent compounds were further tested for A?42 self-aggregation inhibition, demonstrating significant inhibitory effects with up to 72.95% inhibition at 100 µM. These results suggest that N-phenethylpiperidine-hydrazide hydrazones may serve as promising multi-target ligands for the treatment of AD.
- 13 January 2026
- Published by ACG Publications in Bioorganic and Medicinal Chemistry Reports
- Vol. 9 (1)
Synthesis and inhibitory activity of novel N-phenethylpiperidinehydrazide hydrazones against acetylcholinesterase, butyrylcholinesterase, and β-Amyloid (1–42) as potential anti-Alzheimer agents
Novel N-phenethylpiperidine-hydrazide hydrazones were synthesized and evaluated for their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with the most active compounds additionally assessed for their in vitro inhibition of ?-amyloid 42 (A?42) self-aggregation. The synthesized compounds were purified and structurally characterized using FT-IR, ¹H-NMR,13C-NMR, ESI-MS spectroscopy, and elemental analysis. All compounds exhibited inhibitory activity against AChE with IC50 values ranging from 6.32 to 8.24 µM, while some compounds showed moderate inhibition of BChE enzyme. Compound 3g (IC50= 6.32 ± 0.27 µM) and 3i (IC50= 6.32 ± 0.25 µM) showed the highest AChE inhibition, whereas compound 3a exhibited the highest BChE inhibition (IC50= 8.27 ± 0.34 µM). The most potent compounds were further tested for A?42 self-aggregation inhibition, demonstrating significant inhibitory effects with up to 72.95% inhibition at 100 µM. These results suggest that N-phenethylpiperidine-hydrazide hydrazones may serve as promising multi-target ligands for the treatment of AD.
- Open Access
- 13 February 2024
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 22 (1) , 1-9
3-(1H-pyrazole-1-yl/1H-1,2,4-triazole-1-yl)-N-propananilide derivatives: Design, Synthesis and Neuroprotectivity Potential Against 6-OHDA Induced Neurotoxicity Model
Excessive amounts of neuroapoptosis are the underlying cause of neurodegenerative diseases. Bax is a pro-apoptotic member of the B-cell lymphoma-2 family that activates caspases which are the members of the cysteine protease family that play a significant role in the initiation and execution phases of apoptosis. The aim of this study was to design and synthesize a group of N-propananilide derivatives bearing pyrazole or 1,2,4-triazole ring were designed and synthesized to analyze the neuroprotectivity potential against 6-hydroxy-dopamine (6-OHDA). Four compounds possessed protectivity at lower doses were subjected to further studies on caspase-3 and Bax pathway. Designed compounds were synthesized by reacting 1H-pyrazole or 1H-1,2,4-triazole with propananilide intermediates in Dimethylformamide. The neuroprotective activity of the title compounds was analyzed against 6-OHDA-6-OHDA-induced neurotoxicity model. Then, caspase-3 and Bax levels were determined for the selected compounds by Western blot study. All twelve 3-(1H-pyrazole-1-yl/1H-1,2,4-triazole-1-yl)-N-propananilide derivatives possessed neuroprotectivity against the 6-OHDA-induced neurotoxicity model (p≤0.05, **p≤0.001, ***p≤0.005). Compounds 7, 10, 11, and 12 were found to be more active at lower doses. They were subjected to further studies and the results revealed that their protecting activity arose from the decreasing levels of Bax, one of the pro-apoptotic proteins, and c expression levels and caspase-3 proteins. All designed and synthesized derivatives possessed neuroprotectivity against 6-OHDA-induced neurotoxicity in the SH-SY5Y cell line and compounds 7, 10, 11, and 12 revealed that their neuroprotectivity originated from the decreasing Bax expression levels and caspase-3 activation.
- 13 February 2024
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 22 (1) , 1-9
Open Access3-(1H-pyrazole-1-yl/1H-1,2,4-triazole-1-yl)-N-propananilide derivatives: Design, Synthesis and Neuroprotectivity Potential Against 6-OHDA Induced Neurotoxicity Model
Excessive amounts of neuroapoptosis are the underlying cause of neurodegenerative diseases. Bax is a pro-apoptotic member of the B-cell lymphoma-2 family that activates caspases which are the members of the cysteine protease family that play a significant role in the initiation and execution phases of apoptosis. The aim of this study was to design and synthesize a group of N-propananilide derivatives bearing pyrazole or 1,2,4-triazole ring were designed and synthesized to analyze the neuroprotectivity potential against 6-hydroxy-dopamine (6-OHDA). Four compounds possessed protectivity at lower doses were subjected to further studies on caspase-3 and Bax pathway. Designed compounds were synthesized by reacting 1H-pyrazole or 1H-1,2,4-triazole with propananilide intermediates in Dimethylformamide. The neuroprotective activity of the title compounds was analyzed against 6-OHDA-6-OHDA-induced neurotoxicity model. Then, caspase-3 and Bax levels were determined for the selected compounds by Western blot study. All twelve 3-(1H-pyrazole-1-yl/1H-1,2,4-triazole-1-yl)-N-propananilide derivatives possessed neuroprotectivity against the 6-OHDA-induced neurotoxicity model (p≤0.05, **p≤0.001, ***p≤0.005). Compounds 7, 10, 11, and 12 were found to be more active at lower doses. They were subjected to further studies and the results revealed that their protecting activity arose from the decreasing levels of Bax, one of the pro-apoptotic proteins, and c expression levels and caspase-3 proteins. All designed and synthesized derivatives possessed neuroprotectivity against 6-OHDA-induced neurotoxicity in the SH-SY5Y cell line and compounds 7, 10, 11, and 12 revealed that their neuroprotectivity originated from the decreasing Bax expression levels and caspase-3 activation.
- Open Access
- 4 July 2023
- Published by Uluslararasi Insan Bilimleri Dergisi in Journal of Human Sciences
- Vol. 20 (3) , 398-410
An alternative approach for daily perineal care of patients with indwelling urinary catheterization: Photodynamic inactivation with cationic porphyrin derivatives
Background: Catheter-associated urinary tract infections (CAUTI) constitute a significant portion of healthcare-associated infections. Using antiseptic for routine daily perineal care of patients with IUC may reduce CAUTIs. Aim: This study aimed to examine antimicrobial photodynamic inactivation (aPDI) against clinical isolates for use in the daily perineal care of patients with IUC. In addition, it was also aimed to compare the antimicrobial activities of aPDI and 0.1% chlorhexidine gluconate. Methods: In this in-vitro study, cationic porphyrin derivatives (CPDs) were used as photosensitizers in the experiments. CPDs, named PM, PE, PN, and PL were synthesized by the researchers. A diode laser device emitting light with a wavelength of 450 nm (blue light) was used as the light source. Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli and Klebsiella pneumoniae with multidrug-resistant (MDR) properties and Candida albicans were used. Photosensitizer (PS), aPDI, light (L), and control (C) groups in aPDI experiments; control (C) and chlorhexidine gluconate 0.1% groups were used in the chlorhexidine gluconate experiments. Survival was calculated based on CFU/mL in the control group. Results: In experiments, combinations of 25 J/cm² with 6.25 and 3.125 µM PM, PE reduced E. coli, K. pneumoniae, MRSA, and C. albicans survival in the range of 8.70 to 11.53 log₁₀. In aPDI experiments performed with 6.25 and 3.125 µM PN and PL concentrations at the same energy density, reductions in the range of 4.41 to 0.17 log₁₀ were observed in all four clinical isolates. In experiments where 1.5625 µM concentration was used, survival decreased in the range of 8.29 to 10.87 log₁₀ in PM and PE, while antimicrobial activity was limited in PN and PL. In the 0.1% chlorhexidine gluconate experiments, the survival reduction in all four clinical isolates ranged from 8.87 to 10.24 log₁₀. Conclusion: For PM and PE, a very strong aPDI was obtained in C. albicans, E.coli, K. pneumoniae, and MRSA at low concentrations and energy density. The same antimicrobial activity was found in experiments using 0.1% chlorhexidine gluconate. In this context, we would like to inform you that aPDI to be performed with a combination of 25 J/cm² at 6.25 and 3.125 µM concentrations of PM and PE has the potential to be an antiseptic in the daily perineal care of patients with IUC.
- 4 July 2023
- Published by Uluslararasi Insan Bilimleri Dergisi in Journal of Human Sciences
- Vol. 20 (3) , 398-410
Open AccessAn alternative approach for daily perineal care of patients with indwelling urinary catheterization: Photodynamic inactivation with cationic porphyrin derivatives
Background: Catheter-associated urinary tract infections (CAUTI) constitute a significant portion of healthcare-associated infections. Using antiseptic for routine daily perineal care of patients with IUC may reduce CAUTIs. Aim: This study aimed to examine antimicrobial photodynamic inactivation (aPDI) against clinical isolates for use in the daily perineal care of patients with IUC. In addition, it was also aimed to compare the antimicrobial activities of aPDI and 0.1% chlorhexidine gluconate. Methods: In this in-vitro study, cationic porphyrin derivatives (CPDs) were used as photosensitizers in the experiments. CPDs, named PM, PE, PN, and PL were synthesized by the researchers. A diode laser device emitting light with a wavelength of 450 nm (blue light) was used as the light source. Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli and Klebsiella pneumoniae with multidrug-resistant (MDR) properties and Candida albicans were used. Photosensitizer (PS), aPDI, light (L), and control (C) groups in aPDI experiments; control (C) and chlorhexidine gluconate 0.1% groups were used in the chlorhexidine gluconate experiments. Survival was calculated based on CFU/mL in the control group. Results: In experiments, combinations of 25 J/cm² with 6.25 and 3.125 µM PM, PE reduced E. coli, K. pneumoniae, MRSA, and C. albicans survival in the range of 8.70 to 11.53 log₁₀. In aPDI experiments performed with 6.25 and 3.125 µM PN and PL concentrations at the same energy density, reductions in the range of 4.41 to 0.17 log₁₀ were observed in all four clinical isolates. In experiments where 1.5625 µM concentration was used, survival decreased in the range of 8.29 to 10.87 log₁₀ in PM and PE, while antimicrobial activity was limited in PN and PL. In the 0.1% chlorhexidine gluconate experiments, the survival reduction in all four clinical isolates ranged from 8.87 to 10.24 log₁₀. Conclusion: For PM and PE, a very strong aPDI was obtained in C. albicans, E.coli, K. pneumoniae, and MRSA at low concentrations and energy density. The same antimicrobial activity was found in experiments using 0.1% chlorhexidine gluconate. In this context, we would like to inform you that aPDI to be performed with a combination of 25 J/cm² at 6.25 and 3.125 µM concentrations of PM and PE has the potential to be an antiseptic in the daily perineal care of patients with IUC.
- Open Access
- 25 October 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (6) , 1547-1555
Candidate drug molecule-DNA interaction and molecular modelling of candidate drug molecule
Aim: 1,4-dihydropyridine derivative, 1-(3-phenyl propyl)-4-(2-(2-hydroxybenzylidene) hydrazone)-1,4-dihydropyridine (abbreviated as DHP) was synthesized as potential agent for Alzheimer’s disease which is a progressive neurodegenerative brain disorder affecting millions of elderly people. With this study, the electrochemical properties of DHP were investigated and its interaction with DNA was analyzed by differential pulse voltammetry (DPV) and cyclic voltammetry (CV) measurements. In addition, this study aims to determine degradation mechanism of the DHP molecule by Density-functional theory (DFT) in gas and in aqueous phase. Material and Method: Experimental conditions such as immobilization time, the effect of the scan rate, concentration, and the effect of pH were optimized. The method was validated according to validation parameters such as range, precision, linearity, limit of detection (LOD), limit of quantitation (LOQ) and inter/intraday. Results: Linearity study for the calibration curve of DNA and DHP with DPV was calculated in the calibration range 10-100 µg/mL. The LOD and LOQ values were calculated as 3 and 10 µg/mL and intra-day and inter-day repeatability (RSD %) were 1.85 and 3.64 µg/mL, respectively. After the DHP-DNA interaction, the oxidation currents of guanine decreased as a proof of interaction. The activation energy of the most possible path of reaction was calculated, and their thermodynamically most stable state was determined in gas phase. Conclusion: We developed to improve a sensitive, fast and easy detection process for determination of interaction between DHP and DNA.
- 25 October 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (6) , 1547-1555
Open AccessCandidate drug molecule-DNA interaction and molecular modelling of candidate drug molecule
Aim: 1,4-dihydropyridine derivative, 1-(3-phenyl propyl)-4-(2-(2-hydroxybenzylidene) hydrazone)-1,4-dihydropyridine (abbreviated as DHP) was synthesized as potential agent for Alzheimer’s disease which is a progressive neurodegenerative brain disorder affecting millions of elderly people. With this study, the electrochemical properties of DHP were investigated and its interaction with DNA was analyzed by differential pulse voltammetry (DPV) and cyclic voltammetry (CV) measurements. In addition, this study aims to determine degradation mechanism of the DHP molecule by Density-functional theory (DFT) in gas and in aqueous phase. Material and Method: Experimental conditions such as immobilization time, the effect of the scan rate, concentration, and the effect of pH were optimized. The method was validated according to validation parameters such as range, precision, linearity, limit of detection (LOD), limit of quantitation (LOQ) and inter/intraday. Results: Linearity study for the calibration curve of DNA and DHP with DPV was calculated in the calibration range 10-100 µg/mL. The LOD and LOQ values were calculated as 3 and 10 µg/mL and intra-day and inter-day repeatability (RSD %) were 1.85 and 3.64 µg/mL, respectively. After the DHP-DNA interaction, the oxidation currents of guanine decreased as a proof of interaction. The activation energy of the most possible path of reaction was calculated, and their thermodynamically most stable state was determined in gas phase. Conclusion: We developed to improve a sensitive, fast and easy detection process for determination of interaction between DHP and DNA.
- 17 August 2022
- Published by Wiley in Archiv der Pharmazie
- Vol. 355 (12) , e2200152
Design, synthesis, acetylcholinesterase, butyrylcholinesterase, and amyloid‐β aggregation inhibition studies of substituted 4,4ʹ‐diimine/4,4ʹ‐diazobiphenyl derivatives
A series of 4,4′‐diimine/4,4′‐diazobiphenyl derivatives were designed, synthesized, and evaluated for their ability to inhibit both the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, as well as Aβ1–42 aggregation, in vitro. The AChE and BChE inhibition assays demonstrated that all compounds displayed moderate AChE inhibitory activity in the range of IC50 = 5.77–16.22 μM, while they displayed weak or no BChE inhibition. Among the title compounds, compound 2l, 4,4′‐bis(quinolin‐8‐yldiazenyl)‐1,1′‐biphenyl, having a diazo‐quinoline moiety demonstrated the most potent inhibition against AChE with an IC50 value of 5.77 μM. Furthermore, diazo derivatives 2d, 4,4′‐bis[(4‐methoxyphenyl)diazenyl]‐1,1′‐biphenyl, and 2i, 4,4′‐bis(pyridin‐3‐yldiazenyl)‐1,1′‐biphenyl, provided better potency on Aβ1–42 aggregation, with an inhibition value of 74.08% and 78.39% at 100 μM and 55.35% and 61.36% at 25 μM, respectively. Molecular modeling studies were carried out for the most active compound against AChE, compound 2l. All the results suggested that compounds 2d and 2i have better inhibitory potencies on Aβ1–42 aggregation and moderate AChE enzyme activity, and therefore can be highlighted as promising compounds.
- 17 August 2022
- Published by Wiley in Archiv der Pharmazie
- Vol. 355 (12) , e2200152
Design, synthesis, acetylcholinesterase, butyrylcholinesterase, and amyloid‐β aggregation inhibition studies of substituted 4,4ʹ‐diimine/4,4ʹ‐diazobiphenyl derivatives
A series of 4,4′‐diimine/4,4′‐diazobiphenyl derivatives were designed, synthesized, and evaluated for their ability to inhibit both the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, as well as Aβ1–42 aggregation, in vitro. The AChE and BChE inhibition assays demonstrated that all compounds displayed moderate AChE inhibitory activity in the range of IC50 = 5.77–16.22 μM, while they displayed weak or no BChE inhibition. Among the title compounds, compound 2l, 4,4′‐bis(quinolin‐8‐yldiazenyl)‐1,1′‐biphenyl, having a diazo‐quinoline moiety demonstrated the most potent inhibition against AChE with an IC50 value of 5.77 μM. Furthermore, diazo derivatives 2d, 4,4′‐bis[(4‐methoxyphenyl)diazenyl]‐1,1′‐biphenyl, and 2i, 4,4′‐bis(pyridin‐3‐yldiazenyl)‐1,1′‐biphenyl, provided better potency on Aβ1–42 aggregation, with an inhibition value of 74.08% and 78.39% at 100 μM and 55.35% and 61.36% at 25 μM, respectively. Molecular modeling studies were carried out for the most active compound against AChE, compound 2l. All the results suggested that compounds 2d and 2i have better inhibitory potencies on Aβ1–42 aggregation and moderate AChE enzyme activity, and therefore can be highlighted as promising compounds.
- 27 December 2019
- Published by ACG Publications in Organic Communications
- Vol. 12 (4) , 202-209
Synthesis and cholinesterase inhibitory activity studies of some piperidinone derivatives
AA series of a,β-unsaturated carbonyl based piperidinone derivatives were synthesized and evaluated for their abilities to inhibit AChE and BuChE. All compounds exhibited AChE and BuChE inhibitory activity in different ratios. Among the series, compound 1d, (1-benzyl-3,5-bis(4-nitrobenzylidene)piperidine-4-one), was found to be the most potent derivative against AChE (IC50= 12.55 µM) and compound 1g, (1-benzyl-3,5-bis(4-chlorobenzylidene)piperidine-4-one) showed the best anti-BuChE activity (IC50= 17.28 µM). The derivatives exhibited selectivity on AChE enzyme with respect to BuChE. Only compound 1g, bearing chlorine substituents, demonstrated as a dual inhibitor of cholinesterases. Taken together, these results indicated that a,β-unsaturated carbonyl based piperidinone scaffold might be a promising drug candidate for further anti-AD drug development.
- 27 December 2019
- Published by ACG Publications in Organic Communications
- Vol. 12 (4) , 202-209
Synthesis and cholinesterase inhibitory activity studies of some piperidinone derivatives
AA series of a,β-unsaturated carbonyl based piperidinone derivatives were synthesized and evaluated for their abilities to inhibit AChE and BuChE. All compounds exhibited AChE and BuChE inhibitory activity in different ratios. Among the series, compound 1d, (1-benzyl-3,5-bis(4-nitrobenzylidene)piperidine-4-one), was found to be the most potent derivative against AChE (IC50= 12.55 µM) and compound 1g, (1-benzyl-3,5-bis(4-chlorobenzylidene)piperidine-4-one) showed the best anti-BuChE activity (IC50= 17.28 µM). The derivatives exhibited selectivity on AChE enzyme with respect to BuChE. Only compound 1g, bearing chlorine substituents, demonstrated as a dual inhibitor of cholinesterases. Taken together, these results indicated that a,β-unsaturated carbonyl based piperidinone scaffold might be a promising drug candidate for further anti-AD drug development.
- Open Access
- 1 October 2015
- Published by Marmara University in Marmara Pharmaceutical Journal
- Vol. 20 (1) , 21-27-21
Synthesis and cholinesterase inhibitory activity of some phenylacetamide derivatives bearing 1H-pyrazole and 1H-1,2,4-triazole
Synthesis and cholinesterase inhibitory activity of some phenylacetamide derivatives bearing 1H-pyrazole and 1H-1,2,4-triazole
- 1 October 2015
- Published by Marmara University in Marmara Pharmaceutical Journal
- Vol. 20 (1) , 21-27-21
Open AccessSynthesis and cholinesterase inhibitory activity of some phenylacetamide derivatives bearing 1H-pyrazole and 1H-1,2,4-triazole
Synthesis and cholinesterase inhibitory activity of some phenylacetamide derivatives bearing 1H-pyrazole and 1H-1,2,4-triazole